**Core tip:** Recent studies have demonstrated a complex relationship between ghrelin, ghrelin O-acyltransferase (GOAT) and the mammalian target of rapamycin (mTOR) pathway. In our study, we examined the changes of the ghrelin/GOAT axis and the mTOR pathway in the hypothalamus after sleeve gastrectomy (SG). The mRNA and protein levels of ghrelin and GOAT decreased after SG, while NPY mRNA expression did not change. We also found that SG increased the protein levels of p-Akt, p-mTOR and p-S6. The reduction of ghrelin expression and activation of the mTOR pathway might have opposite effects on food intake. These findings might explain the weight, glucose and food intake regain after SG.

INTRODUCTION
============

Obesity and type-2 diabetes mellitus (T2DM) are closely related epidemic diseases with increasing incidence rates worldwide. Lifestyle factors such as high-fat diet, lack of physical activity, genetic and environmental factors are important causes of diabetes. As one of the most commonly used bariatric surgeries, sleeve gastrectomy (SG) can effectively reduce obesity and improve metabolic symptoms by weight loss and hormonal change. Recent studies have found that weight loss and T2DM remission may be related to ghrelin, bile acids and microbiota changes after SG\[[@B1]\].

Ghrelin, mainly found in the stomach, is an endogenous ligand for the growth hormone secretagogue receptor type 1a (GHS-R1a) and has two major molecular forms, acylated ghrelin (AG) and unacylated ghrelin (UAG)\[[@B2]-[@B4]\]. As the activated form of ghrelin, AG is best known for its effect on growth hormone-releasing neurons. For instance, AG was shown to increase neuropeptide Y (NPY) mRNA expression levels by the mammalian target of rapamycin (mTOR) in the hypothalamus\[[@B5],[@B6]\]. The enzyme responsible for transforming UAG to AG was identified in 2008 and named ghrelin O-acyltransferase (GOAT)\[[@B7]\]. A recent study found that AG could regulate GOAT expression in the stomach\[[@B8]\] and that the widespread expression of GOAT corresponded to the widespread distribution of ghrelin expression, *e.g*., in the pancreas, stomach and hypothalamus\[[@B8],[@B9]\]. Multiple studies have demonstrated that both ghrelin and GOAT play important roles in the regulation of obesity, blood glucose and insulin\[[@B5],[@B10],[@B11]\]. However, it is not clear whether the ghrelin/GOAT axis in the hypothalamus (*via* autocrine/paracrine signaling) is involved in the maintenance of blood glucose concentrations and energy homeostasis by restricting food intake after SG.

Recent studies suggested that the mTOR pathway may play an important role and have complex impact on several cellular functions, such as cell growth, weight loss, food intake and even insulin resistance\[[@B12]-[@B16]\]. It was also demonstrated that both energy deprivation and AG can activate the mTOR pathway to affect food intake\[[@B6],[@B17]\]. Meanwhile, insulin inhibits GOAT expression *via* the mTOR pathway in islet cells\[[@B3]\] and SG can suppress the mRNA levels of preproghrelin and GOAT in a remnant stomach\[[@B18]\]. However, changes of the Ghrelin/GOAT axis and the mTOR pathway in the hypothalamus after SG have not yet been investigated. The aim of this study was to evaluate these changes to explain the mechanism of SG from a central point of view.

MATERIALS AND METHODS
=====================

Animals and experimental protocol
---------------------------------

Seventy-seven male Sprague-Dawley rats (6 wk of age, weight: 150-180 g) were obtained from the Laboratory Animal Center of the Second Military Medical University. Equipment and reagents were obtained from the following sources: electronic analytical balance (Libror AEL-200 type, Japan); Roche glucometer (ACCU-CHEK^®^ Performa, Roche Diagnostics); streptozotocin (Sigma-Aldrich, China); rat total ghrelin, AG and Insulin ELISA assay kit (R&D system, United States); ghrelin, GHSR, GOAT, p-AKT(s473), mTOR, p-mTOR(s2448), P70s6k, GAPDH antibody (Abcam, United States); and p-S6 (s235/236) antibody (Sigma-Aldrich, United States). All procedures conformed to the institutional standards of The Second Military Medical University Animal Care and Use Committee (approval no. SCXK(H) 2013-0016).

Establishment of the animal model
---------------------------------

Rats had a mean body mass of 173.82 ± 14.32 g and were randomly divided into NF (fed normal fodder, *n* = 20) or HF groups (fed high-sugar and high-fat fodder, *n* = 57). During the 2-mo experiment, all rats were housed at 20-25 °C and 40%-60% relative humidity. Rats with a 20% higher body mass than the average weight of the NF group\[[@B19]\] were defined as obese rats. Noninsulin-dependent diabetes mellitus was induced in overnight-fasted rats by a single intraperitoneal injection of 45 mg/kg streptozotocin. Blood glucose was measured from the tail vein once daily within 3 d after injecting streptozotocin. Only the rats with an average blood glucose concentration \> 16.7 mmol/L were included as successful T2DM models. Of all rats, 32 models were successfully established, with a success rate of 56.14%.

Animal grouping
---------------

Of the 32 T2DM model rats, two rats died after SG. The remaining 30 rats were randomly divided into three groups: non-operation (S0 group, *n* = 10), sham operation (Sh group, *n* = 10) or sleeve gastrectomy group (SG group, *n* = 10).

Surgical operation and intervention study
-----------------------------------------

All rats of the operation groups (both Sh and SG) were food- and water-deprived for 12 h before surgery. The rats were anesthetized by an i.p. injection of 0.3% sodium pentobarbital (50 mg/kg) and observed until corneal and pain reflexes were absent. A hypodermic injection of 0.9% sodium chloride solution (20 mL) and an intramuscular injection of penicillin sodium (800000 IU) were given to prevent dehydration and infection before the surgery began.

A 3-cm incision was made 1 cm below the xiphoid process. After opening the abdominal cavity and exposing the stomach, the ligaments surrounding the stomach and gastroepiploic tissues were broken. A 3-5-mm transverse incision was made along the greater curvature to empty the stomach contents. This step could avoid the contents outflowing quickly to prevent abdominal infection. After empting the stomach, the gastric fundus and a large portion of the gastric body (70% of the total stomach) were resected (Figure [1A](#F1){ref-type="fig"}). The residual stomach was then closed by a single-layer continuous suture using 6-0 absorbable lines (Figure [1B](#F1){ref-type="fig"}). Before closure of the skin, the abdominal cavity was rinsed with a warm 0.9% sodium chloride solution (20-30 mL).

![An intact stomach before SG (A) and the remnant stomach (↓) and resected gastric fundus (↑↑) after SG (B). The ↓ appearing in the figure A means that the gastric fundus and a large portion of the gastric body should be resected.](WJG-23-6231-g001){#F1}

Sham-operated rats underwent a similar procedure as the SG group, including anesthesia, a 3-5-mm transverse incision was made along the greater curvature near the pylorus to empty stomach contents. After empting the stomach, the incision was extended to 2 cm, with a waiting time that corresponded to the resection time in SG rats, followed by stomach closure. Rats that were operated on were allowed access to water 2 h after surgery, but were fasted for 24 h after operation. After 2-3 d, they were fed a non-residue diet; and after recovery, they consumed their preoperative diet.

Body mass, food intake, oral glucose tolerance test, ghrelin measurements
-------------------------------------------------------------------------

Body mass was measured once every 5 d preoperatively and once a day postoperatively for 8 wk. Food intake was measured by recording the total amount of fodder consumed per week. To perform the oral glucose tolerance test (OGTT), all rats were fasted overnight and received a 50% glucose solution (1 g/kg) by oral gavage\[[@B20]\]. Blood was collected from the orbital vein to measure the glucose and insulin concentrations at 0, 15, 30, 60, 90 and 120 min after glucose infusion at the first day (rats were 6 wk old), preoperative day 3 and postoperative week 8. The area under the glucose curve (AUC-glucose), AUC-insulin and HOMA-IR (fasting insulin × fasting glucose/22.5) were calculated. The blood collected from the OGTT at 0 min was also used to measure AG and TG.

Hypothalamic tissue was collected for Western blotting and real-time polymerase chain reaction (PCR). All rats were sacrificed by an overdose of anesthesia. Sections containing the hypothalamus were cut according to the rat brain atlas of Paxinos and Watson and immediately frozen in liquid nitrogen\[[@B21]\].

Western blot analysis
---------------------

The hypothalamus was crushed in PMSF lysate (50 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 1% Triton X-100, 100 μg/mL PMSF) for 30 min and then centrifuged at 12000 rpm for 5 min. Protein concentration was measured by the BCA protein assay reagent. A total of 40 μg protein was separated by a 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. All membranes were incubated overnight at 4 °C with primary antibodies. They were then incubated with secondary antibodies at room temperature for 1 h and visualized using the GChemiDoc MP imaging system and image lab software (Bio-Rad, United States). All results were expressed as target protein/GAPDH ratio.

Real-time PCR analysis
----------------------

Total RNA was extracted with Trizol Reagent (Invitrogen, United States). Then, 2 μg total RNA was reversely transcribed with Oligo (dT) primer and M-MLV Reverse Transcriptase (Promega, United States), according to the manufacturer's instructions. The complementary DNA was used for real-time PCR, and a final volume of 20 μL was made as follows: 10 μL 2 × SYBR premix exTaq (TaKaRa, China), 0.8 μL forward and reverse primers (2.5 μmol/L, 5 μL cDNA, 4.2 μL ddH~2~O). PCR and data collection were performed on a CFX Connect™ Real-Time PCR Detection System (Takara), and data analysis was operated with the 2^-ΔΔCt^ method normalized to the endogenous control β-actin. Primers used in real-time PCR were as follows: Rat preproghrelin: 5′-AAGCCCAGCAGAGAAAGGAATC-3′ (forward); 5′-CAACATCGAAGGGAGCATTGAAC-3′ (reverse). Rat GOAT: 5′-ATTTGTGAAGGGAAGGTGGAG-3′ (forward); 5′-CAGGAGAGCAGGGAAAAAGAG-3′ (reverse). Rat NPY: 5′-GGCCAGATACTACTCCGCTC-3′ (forward); 5′-GTCTTCAAGCCTTGTTCTGGG-3′ (reverse). Rat β-actin: 5′-GAGACCTTCAACACCCCAGCC-3′ (forward); 5′-TCGGGGCATCGGAACCGCTCA-3′ (reverse).

Statistical analysis
--------------------

Data are presented as the mean ± SD. SPSS 20.0 (IBM, New York, United States) was used for statistical analyses, and GraphPad Prism 6.0c (GraphPad Software, San Diego, CA, United States) was used to edit images. Statistical indicators between the three groups (S0, Sh and SG) were determined by one-way ANOVA, followed by least significance difference (LSD) *post hoc* comparison. The statistical indicator between two time points in one group was determined by a paired *t* test, whereas Student's *t* test was used to compare the means of two independent groups at the same time point.

RESULTS
=======

Body mass and food intake
-------------------------

Baseline body mass before surgery did not differ between groups (*P* \> 0.05). Rats in the Sh group and SG group weighed significantly less in the first postoperative week, which gradually normalized and increased in the second week after surgery when rats continued with their preoperative diet. The minimum weight was 442.17 ± 9.57 g in Sh rats at postoperative day 7 and 409.25 ± 12.7 g in SG rats at postoperative day 9. The weight in the sham group was restored to preoperative levels at postoperative day 17. The weight of SG rats remained low and did not reach baseline levels (Figure [2](#F2){ref-type="fig"}).

![Body mass before and after surgery. Statistical differences were analyzed by one-way ANOVA followed by the LSD-*t* test. ^a^*P* \< 0.05, S0 *vs* SG; ^c^*P* \< 0.05, S0 *vs* Sh; ^e^*P* \< 0.05, Sh *vs* SG. LSD: Least significant difference; Sh: Sham operation group; SG: Sleeve gastrectomy.](WJG-23-6231-g002){#F2}

Food intake was significantly decreased in the Sh group and the SG group but was consistently higher in the Sh group compared to the SG group (Figure [3](#F3){ref-type="fig"}).

![Food intake after surgery. Statistical differences were analyzed by one-way ANOVA followed by the least significant difference-*t* test. ^a^*P* \< 0.05, S0 *vs* SG; ^c^*P* \< 0.05, S0 *vs* Sh; ^e^*P* \< 0.05, Sh *vs* SG. LSD: Least significant difference; Sh: Sham operation group; SG: Sleeve gastrectomy.](WJG-23-6231-g003){#F3}

OGTT
----

**Fasting blood glucose:** Fasting blood glucose did not differ between treatment groups at the first day (*P* \> 0.05) and significantly increased in obese model rats (*P* \< 0.05). Eight weeks after surgery, the fasting blood glucose levels in the SG group were significantly lower than in the S0 and Sh groups (*P* \< 0.05; Table [1](#T1){ref-type="table"})

###### 

Changes in fasting blood glucose

  **Time points**      **Fasting blood glucose (mmol/L)**                                                         
  -------------------- --------------------------------------------- -------------------------------------------- -----------------------------------------------------------------------------
  First day            6.18 ± 1.19                                   5.89 ± 1.12                                  6.19 ± 0.94
  Preoperative         15.03 ± 2.4[a](#T1FN1){ref-type="table-fn"}   15.9 ± 1.2[a](#T1FN1){ref-type="table-fn"}   15.88 ± 2.32[a](#T1FN1){ref-type="table-fn"}
  Postoperative wk 8   14.55 ± 1.29                                  14.29 ± 1.69                                 9.00 ± 1.17[c](#T1FN2){ref-type="table-fn"}[e](#T1FN3){ref-type="table-fn"}

Statistical differences among the three groups were analyzed by one-way ANOVA followed by LSD-*t* and between two time points in one group using a paired *t* test.

*P* \< 0.05, preoperative *vs* first day levels in the same group;

*P* \< 0.05, postoperative *vs* preoperative levels in the SG group;

*P* \< 0.05, SG *vs* S0 and Sh postoperatively. LSD: Least significant difference; Sh: Sham operation group; SG: Sleeve gastrectomy.

**Blood glucose and AUC-glucose:** Blood glucose levels of the S0, Sh and SG groups did not differ among all the time points at the first day but significantly increased as rats became obese. Blood glucose levels and AUC-glucose in the SG group significantly decreased after surgery and were significantly lower than in the S0 and Sh groups (Figure [4](#F4){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

###### 

Oral glucose tolerance test of blood glucose

  **Time points (min)**   **Blood glucose (mmol/L)**                                                                                                                                                                                                          
  ----------------------- ---------------------------- ------------- ------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- -------------- -------------- ------------------------------------------------------------------------------
  0                       6.18 ± 1.19                  5.89 ± 1.12   6.19 ± 0.94   15.03 ± 2.40[a](#T2FN1){ref-type="table-fn"}   15.90 ± 1.20[a](#T2FN1){ref-type="table-fn"}   15.88 ± 2.32[a](#T2FN1){ref-type="table-fn"}   14.55 ± 1.29   14.29 ± 1.69   9.00 ± 1.17[c](#T2FN2){ref-type="table-fn"}[e](#T2FN3){ref-type="table-fn"}
  15                      6.18 ± 1.17                  6.42 ± 1.22   6.66 ± 1.27   20.82 ± 3.80[a](#T2FN1){ref-type="table-fn"}   21.35 ± 4.13[a](#T2FN1){ref-type="table-fn"}   20.84 ± 4.41[a](#T2FN1){ref-type="table-fn"}   19.06 ± 2.68   18.39 ± 2.42   10.12 ± 1.07[c](#T2FN2){ref-type="table-fn"}[e](#T2FN3){ref-type="table-fn"}
  30                      7.15 ± 1.03                  7.13 ± 1.27   7.03 ± 1.32   21.76 ± 3.45[a](#T2FN1){ref-type="table-fn"}   22.13 ± 2.96[a](#T2FN1){ref-type="table-fn"}   21.15 ± 2.86[a](#T2FN1){ref-type="table-fn"}   20.09 ± 4.02   22.47 ± 3.63   11.21 ± 1.02[c](#T2FN2){ref-type="table-fn"}[e](#T2FN3){ref-type="table-fn"}
  60                      7.22 ± 1.36                  7.07 ± 1.38   6.93 ± 1.02   22.23 ± 3.47[a](#T2FN1){ref-type="table-fn"}   22.23 ± 4.03[a](#T2FN1){ref-type="table-fn"}   22.96 ± 2.78[a](#T2FN1){ref-type="table-fn"}   20.32 ± 3.26   19.80 ± 3.49   11.75 ± 0.95[c](#T2FN2){ref-type="table-fn"}[e](#T2FN3){ref-type="table-fn"}
  90                      6.45 ± 1.21                  6.27 ± 1.31   6.58 ± 1.31   17.72 ± 2.19[a](#T2FN1){ref-type="table-fn"}   18.48 ± 2.54[a](#T2FN1){ref-type="table-fn"}   17.43 ± 2.61[a](#T2FN1){ref-type="table-fn"}   18.30 ± 2.50   18.81 ± 2.90   8.76 ± 1.01[c](#T2FN2){ref-type="table-fn"}[e](#T2FN3){ref-type="table-fn"}
  120                     6.00 ± 0.92                  5.89 ± 0.65   5.58 ± 0.75   15.47 ± 1.55[a](#T2FN1){ref-type="table-fn"}   15.04 ± 1.58[a](#T2FN1){ref-type="table-fn"}   15.67 ± 1.44[a](#T2FN1){ref-type="table-fn"}   14.08 ± 1.00   15.07 ± 1.63   6.98 ± 1.13[c](#T2FN2){ref-type="table-fn"}[e](#T2FN3){ref-type="table-fn"}

Statistical differences among the three groups were analyzed by one-way ANOVA followed by LSD-*t* test and between two time points in one group using a paired *t* test.

*P* \< 0.05, preoperative *vs* first day levels in the same group at the same time point;

*P* \< 0.05, postoperative *vs* preoperative levels in the SG group;

*P* \< 0.05, SG *vs* S0 and Sh postoperatively. LSD: Least significant difference; Sh: Sham operation group; SG: Sleeve gastrectomy.

![Oral glucose tolerance test curve of blood glucose at the first day (A), preoperatively (B) and postoperatively (C) and AUC-blood glucose (D). Statistical differences among the three groups at the same time point were analyzed by one-way ANOVA followed by LSD-*t* test and between two time points in one group using paired *t* test. C: ^a^*P* \< 0.05, SG *vs* S0 and Sh at the same time point; ^c^*P* \< 0.05, preoperative or postoperative *vs* first day levels in the same group; ^e^*P* \< 0.05, postoperative *vs* preoperative levels in the SG group; ^g^*P* \< 0.05, SG *vs* S0 and Sh postoperatively. OGTT: Oral glucose tolerance test; Sh: Sham operation group; SG: Sleeve gastrectomy; LSD: Least significant difference.](WJG-23-6231-g004){#F4}

**Blood insulin and AUC-insulin:** Fasting insulin and maximal insulin were significantly increased, and the maximal insulin excretion time was at the 90^th^ min in all groups after glucose loading at preoperative day 3, while the maximal insulin excretion time was at the 60^th^ min after glucose loading on the first day. Compared with the S0 and Sh groups, the SG group had lower fasting insulin and maximal insulin concentrations. The maximal insulin excretion time in SG rats was at the 60^th^ min again. AUC-glucose and AUC-insulin were increased in all obese model groups and were significantly reduced in the SG group at 8 weeks after surgery. HOMA-IR, which reflects insulin resistance, was also significantly reduced in the SG group (Table [3](#T3){ref-type="table"}, Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}).

###### 

Oral glucose tolerance test of blood insulin

  **Time points (min)**   **Blood insulin (mU/L)**                                                                                                                                                                                                             
  ----------------------- -------------------------- -------------- --------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- -------------- -------------- ------------------------------------------------------------------------------
  0                       13.06 ± 2.21               13.03 ± 2.01   12.97 ± 2.63    24.79 ± 3.06[a](#T3FN1){ref-type="table-fn"}   26.48 ± 2.19[a](#T3FN1){ref-type="table-fn"}   24.37 ± 2.51[a](#T3FN1){ref-type="table-fn"}   23.33 ± 1.81   27.58 ± 2.24   15.21 ± 2.87[c](#T3FN2){ref-type="table-fn"}[e](#T3FN3){ref-type="table-fn"}
  15                      19.16 ± 1.57               19.04 ± 1.83   20.63 ± 1.17    28.66 ± 3.20[a](#T3FN1){ref-type="table-fn"}   29.38 ± 3.33[a](#T3FN1){ref-type="table-fn"}   28.72 ± 2.39[a](#T3FN1){ref-type="table-fn"}   29.78 ± 2.86   32.95 ± 2.65   25.71 ± 7.73[c](#T3FN2){ref-type="table-fn"}[e](#T3FN3){ref-type="table-fn"}
  30                      40.90 ± 3.15               42.65 ± 9.89   41.64 ± 12.51   35.47 ± 3.36[a](#T3FN1){ref-type="table-fn"}   36.27 ± 3.21[a](#T3FN1){ref-type="table-fn"}   35.33 ± 4.68[a](#T3FN1){ref-type="table-fn"}   36.49 ± 3.25   36.78 ± 2.05   47.93 ± 3.31[c](#T3FN2){ref-type="table-fn"}[e](#T3FN3){ref-type="table-fn"}
  60                      63.46 ± 5.30               62.43 ± 6.01   65.38 ± 3.45    54.76 ± 2.85[a](#T3FN1){ref-type="table-fn"}   59.37 ± 2.12                                   59.81 ± 4.63[a](#T3FN1){ref-type="table-fn"}   57.36 ± 3.51   58.08 ± 2.77   69.05 ± 1.74[c](#T3FN2){ref-type="table-fn"}[e](#T3FN3){ref-type="table-fn"}
  90                      22.55 ± 1.80               21.81 ± 2.65   21.68 ± 3.23    80.35 ± 2.42[a](#T3FN1){ref-type="table-fn"}   82.68 ± 2.02[a](#T3FN1){ref-type="table-fn"}   80.68 ± 4.13[a](#T3FN1){ref-type="table-fn"}   79.79 ± 5.66   82.14 ± 3.46   30.55 ± 7.66[c](#T3FN2){ref-type="table-fn"}[e](#T3FN3){ref-type="table-fn"}
  120                     14.30 ± 1.82               13.25 ± 1.67   13.14 ± 2.02    66.15 ± 4.38[a](#T3FN1){ref-type="table-fn"}   70.11 ± 8.05[a](#T3FN1){ref-type="table-fn"}   71.52 ± 4.20[a](#T3FN1){ref-type="table-fn"}   71.26 ± 7.88   71.76 ± 6.63   18.23 ± 4.95[c](#T3FN2){ref-type="table-fn"}[e](#T3FN3){ref-type="table-fn"}

Statistical differences among the three groups were analyzed by one-way ANOVA followed by LSD-*t* and between two time points in one group using a paired *t* test.

*P* \< 0.05, preoperative *vs* first day levels in the same group at the same time point;

*P* \< 0.05, postoperative *vs* preoperative levels in the SG group;

*P* \< 0.05, SG *vs* S0 and Sh postoperatively. LSD: Least significant difference; Sh: Sham operation group; SG: Sleeve gastrectomy.

![Oral glucose tolerance test curve of blood insulin at the first day (A), preoperatively (B) and postoperatively (C) and AUC-blood insulin (D). Statistical differences among the three groups at the same time point were analyzed by one-way ANOVA followed by LSD-*t* test and between two time points in one group using paired t test. ^a^*P* \< 0.05, SG *vs* S0 and Sh at the same time point; ^c^*P* \< 0.05, preoperative or postoperative *vs* first day levels in the same group; ^e^*P* \< 0.05, postoperative *vs* preoperative levels in the SG group; ^g^*P* \< 0.05, SG *vs* S0 and Sh postoperatively. OGTT: Oral glucose tolerance test; Sh: Sham operation group; SG: Sleeve gastrectomy; LSD: Least significant difference.](WJG-23-6231-g005){#F5}

![HOMA-IR in the S0, sham operation group and sleeve gastrectomy at the first day, preoperatively and postoperatively. Statistical differences among the three groups at the same time point were analyzed by one-way ANOVA followed by the LSD-*t* test and between two time points in the same group using paired *t* test. ^a^*P* \< 0.05, preoperative or postoperative *vs* first day levels in the same group; ^c^*P* \< 0.05, postoperative *vs* preoperative levels in the SG group; ^e^*P* \< 0.05, SG *vs* S0 and Sh postoperatively. Sh: Sham operation group; SG: Sleeve gastrectomy.](WJG-23-6231-g006){#F6}

TG and AG
---------

The obese rats showed a lower serum TG level and no change in AG, but the ratio of AG/TG was increased. When compared with the S0 and Sh groups, the SG group showed decreased TG (1482.03 ± 26.55, 1481.49 ± 23.30 and 1206.63 ± 52.02 ng/L, respectively, *P* \< 0.05) but unchanged AG (153.06 ± 13.74, 155.37 ± 19.30 and 144.44 ± 16.689 ng/L, respectively, *P* \> 0.05). As a result, the ratio of AG/TG was further increased in the SG group (0.103 ± 0.009, 0.105 ± 0.013 and 0.12 ± 0.016, respectively, *P* \< 0.05) (Figure [7](#F7){ref-type="fig"}).

![Changes of total ghrelin (A), acylated ghrelin (B) and acylated ghrelin/total ghrelin (C) at the first day, preoperatively and postoperatively. Statistical differences among the three groups at the same time point were analyzed by one-way ANOVA followed by the LSD-*t* test and between two time points in the same group using paired *t* test. ^a^*P* \< 0.05, preoperative or postoperative *vs* first day levels in the same group; ^c^*P* \< 0.05, postoperative *vs* preoperative levels in the SG group; ^e^*P* \< 0.05, SG *vs* S0 and Sh postoperatively. AG: Acylated ghrelin; TG: Total ghrelin; Sh: Sham operation group; SG: Sleeve gastrectomy; LSD: Least significant difference.](WJG-23-6231-g007){#F7}

mRNA expression levels of preproghrelin, GOAT and NPY in the hypothalamus
-------------------------------------------------------------------------

The mRNA expression levels of preproghrelin and GOAT were lower in the SG group than in the S0 group, while NPY mRNA expression did not differ between groups (Table [4](#T4){ref-type="table"}).

###### 

Hypothalamic mRNA expression of preproghrelin, ghrelin O-acyltransferase and neuropeptide Y

  **X-mRNA/β-acting-mRNA**   **S0**        **SG**
  -------------------------- ------------- ---------------------------------------------
  Preproghrelin              0.63 ± 0.12   0.50 ± 0.11[a](#T4FN1){ref-type="table-fn"}
  GOAT                       0.96 ± 0.09   0.87 ± 0.08[a](#T4FN1){ref-type="table-fn"}
  NPY                        0.61 ± 0.04   0.65 ± 0.07

Hypothalamic mRNA expression of preproghrelin, GOAT and NPY was quantified using PCR and expressed as the ratio to the β-actin mRNA. Statistical differences between the two groups were analyzed using Student's *t* test.

*P* \< 0.05, S0 *vs* SG. GOAT: Ghrelin O-acyltransferase; SG: Sleeve gastrectomy; NPY: Neuropeptide Y.

Ghrelin, GHSR and GOAT protein in the hypothalamus
--------------------------------------------------

Ghrelin and GOAT protein expression was significantly reduced in SG rats, while the level of GHSR protein expression was increased (Figure [8](#F8){ref-type="fig"}).

![Ghrelin/ghrelin O-acyltransferase axis in hypothalamus. A: Expression of ghrelin, GOAT and GHSR protein in the hypothalamus. GAPDH was used as an internal control; B: Ratio of target protein gray value to GAPDH gray value. Statistical differences between the two groups were analyzed by Student's *t* test. GOAT: Ghrelin O-acyltransferase; SG: Sleeve gastrectomy.](WJG-23-6231-g008){#F8}

Protein expression of the mTOR pathway in the hypothalamus
----------------------------------------------------------

The levels of p-Akt, p-mTOR and p-S6 protein expression were higher in the SG group, while the protein expression levels of mTOR and P70S6K did not differ between the Sh and SG groups (Figure [9](#F9){ref-type="fig"}).

![The mammalian target of rapamycin pathway in hypothalamus. A: Protein expression of the mTOR pathway in the hypothalamus. GAPDH was used as an internal control; B: Ratio of target protein gray value to GAPDH gray value. Statistical differences between the two groups were analyzed by Student's *t* test. SG: Sleeve gastrectomy; mTOR: Mammalian target of rapamycin.](WJG-23-6231-g009){#F9}

DISCUSSION
==========

As a bariatric surgery, SG can not only significantly reduce body weight but also effectively improve T2DM and obesity-induced metabolic complications\[[@B1]\]. More and more surgeons worldwide choose SG, especially in Asia, because of the less difficulty and complications of SG when compared with other bariatric surgeries. As the number of SGs is increasing, the surgeons' viewpoint of SG changes from bariatric surgery to metabolic surgery. However, when compared with Roux-en-Y gastric bypass (RYGB), which is regarded as the "gold standard" in metabolic surgery, the effect of SG on improving metabolic symptoms and weight loss is seemingly imperfect\[[@B22]-[@B24]\]. Weight and blood glucose regain is still the most disputed problem after SG. Our data showed that body mass, food intake, fasting blood glucose, postprandial blood glucose, AUC-glucose, AUC-insulin and HOMA-IR were significantly reduced after SG. However, the body mass levels at postoperative week 8 were comparable to the preoperative level. Remarkably, hyperglycemia and insulin resistance were significantly improved. The mechanism of SG is still unclear; the most important mechanisms are believed to be the restriction of calories and the complex hormonal changes. One of these hormonal changes include the markedly reduced ghrelin levels after removal of the gastric fundus.

Previous studies demonstrated that low plasma ghrelin levels are beneficial in elevating fasting insulin levels and improving hyperglycemia, insulin resistance and obesity, while higher levels of ghrelin inhibit insulin release in the pancreas and enhance the food intake signals in the hypothalamus\[[@B25],[@B26]\]. Furthermore, ghrelin gene knock-out mice had lower blood glucose and higher blood insulin levels\[[@B5]\]. As one of the two existing forms of ghrelin in the body, AG is commonly considered the active form due to its "negative" effect on blood glucose metabolism and positive effect on food intake signals in the hypothalamus\[[@B27],[@B28]\], whereas UAG can antagonize AG's effects\[[@B29]-[@B31]\]. Recent studies found that obese individuals have lower blood ghrelin levels but no change in serum AG levels or the ratio of AG/UAG. SG can further reduce serum UAG but not AG levels and increase the ratio of AG/UAG\[[@B32]\]. Our data demonstrated that the level of TG was significantly decreased in obese rats; however, AG levels were unchanged and the ratio of AG/TG was increased. As shown in Figure [7](#F7){ref-type="fig"}, SG can further reduce the serum TG levels after SG-induced resection of the gastric fundus. However, AG was still not changed, but the ratio of AG/TG was further increased. Since SG can only reduce the levels of serum TG or UAG, it is unclear how SG can improve obesity and T2DM with increasing ratios of AG/TG or AG/UAG. Previous studies mentioned that ghrelin secretion depends on a specific secretion cue related to fasting and feeding\[[@B33]\], which should be abolished by SG. However, ours and other studies did not confirm whether SG really abolished ghrelin's special cyclic secretion. We propose that altered ghrelin secretion cues might be more important than plasma TG, AG or UAG in SG-induced improvement of obesity and metabolic symptoms.

AS is required for active ghrelin to bind with and activate its receptor; GOAT is essential for octanoylation of ghrelin\[[@B34]\]. A number of studies demonstrated that GOAT mainly exists in tissues that play an important role in the regulation of food intake, blood glucose metabolism and energy homeostasis, such as the stomach, hypothalamus and pancreas\[[@B8]\]. However, the relationship between GOAT expression and energy homeostasis is inconsistent. Gonzalez\[[@B35]\] found that a 30% food reduction for 21 d increased GOAT expression in the gastric mucosa, while a 48-h fasting period had no effect on GOAT expression in rats. On the contrary, other studies reported that GOAT expression was decreased after food restriction\[[@B36],[@B37]\]. Body energy level is not the only factor determining GOAT expression. Gahete et al\[[@B8]\] found that AG could increase GOAT expression in the stomach, whereas insulin inhibited the expression of GOAT mRNA *via* the mTOR pathway\[[@B3]\]. In our study, both mRNA and protein expression levels of ghrelin and GOAT significantly decreased after SG, while GHSR protein expression significantly increased. As mentioned above, this phenomenon may be related to the abolishment of ghrelin's special cyclic secretion. The "override inhibition" theory\[[@B38]\] describes a phenomenon in which hormones, normally secreted in response to an episodic stimulus, are paradoxically inhibited when that stimulus occurs continuously. Therefore, SG may eliminate the periodic effect of cyclic ghrelin on the hypothalamus, resulting in a reduced expression level of preproghrelin mRNA and ghrelin protein, as well as a GHSR compensatory increase. The reduction of GOAT mRNA and protein may be due to a local ghrelin decrease and energy deprivation after SG. Although ghrelin was significantly decreased, the level of NPY mRNA expression in SG rats did not change, which may be related to the activation of the mTOR pathway in the negative energy balance of the hypothalamus after SG.

Several studies have shown that the hypothalamic mTOR pathway plays a major role in the regulation of energy homeostasis and food intake\[[@B6]\]. A recent study demonstrated that energy deprivation and administration of ghrelin into the 4^th^ ventricle led to increased levels of p-mTOR and increased NPY mRNA expression and promoted feeding through the activation of the hypothalamic mTOR pathway. Moreover, rapamycin could significantly inhibit mTOR activity and reduce food intake\[[@B6],[@B17]\]. Our data suggest that SG can significantly increase the protein levels of p-Akt, p-mTOR and p-S6 in the hypothalamus. As a classic restrictive metabolic surgery, it is possible that SG first reduces the calorie intake, which then activates the mTOR pathway. Therefore, the activation of the mTOR pathway may be the reason for the increased NPY level after SG.

One of the limitations of our study is that we did not compare SG with other restrictive metabolic surgeries. Kawasaki et al\[[@B21]\] found no difference in hypothalamic mRNA expression of NPY between normally fed rats and SG rats. However, when compared with gastric banding rats, the NPY mRNA expression in SG rats was significantly lower. The reduction of ghrelin expression and activation of the mTOR pathway might have an opposite effect on food intake after SG.

Overall, altered glucose metabolism and food intake changes following SG should be divided into peripheral and central changes. In the periphery, SG can significantly reduce food intake by decreasing gastric volume and changing blood ghrelin levels. Further studies should focus on how SG changes ghrelin's special cyclic secretion, especially AG's. In the center, as mentioned above, we found two opposite factors for the regulation of food intake. A recent study has shown that a residual stomach expansion occurred in more than 50% of the SG patients over a short-term period\[[@B39],[@B40]\]. Increased food intake may be the most important factor for the residual stomach expansion. The results of our study provide a clue for further studies on SG and its regulation of food intake from a central point of view.

COMMENTS
========

Background
----------

Sleeve gastrectomy (SG), which is a classic restrictive metabolic surgery, becomes more and more popular worldwide because of its less difficulty and complications. However, weight and blood glucose regain is still the most disputed problems after SG. Increasing food intake might be the most important reason for these problems.

Research frontiers
------------------

This study aimed to examine the changes of the ghrelin/ghrelin O-acyltransferase (GOAT) axis and the mammalian target of rapamycin (mTOR) pathway in the hypothalamus after SG. These changes provide a clue for further studies on SG and its regulation of food intake from a central point of view.

Innovations and breakthroughs
-----------------------------

The authors compared between SG rats and non-operation rats in ghrelin/GOAT axis and the mTOR pathway in the hypothalamus, and found that SG could suppress mRNA and protein levels of preproghrelin and GOAT but did not change neuropeptide Y mRNA expression. The protein levels of p-Akt, p-mTOR and p-S6 were higher in the SG group, which indicates that the hypothalamic mTOR pathway was activated after SG on the postoperative week 8.

Applications
------------

The findings in this study suggest that patients who underwent SG still need to control food intake for better improvement of obesity and glucose metabolism.

Terminology
-----------

SG is a novel procedure of metabolic surgery to remove at least 70% of stomach from the greater curvature. Ghrelin, mainly found in the stomach, could increase food intake and should be inhibited after SG. GOAT is essential for transforming unacylated ghrelin to acylated ghrelin. The mTOR pathway has an important and complex impact on several cellular functions, such as cell growth, weight loss, food intake and even insulin resistance.

Peer-review
-----------

The authors examined changes of the ghrelin/GOAT axis and the mTor pathway in the hypothalamus after SG. This is a carefully done study and the findings are of considerable interest.
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